Apomorphine
- Atc Codes:G04BE07#N04BC07
- CAS Codes:41372-20-7#314-19-2#58-00-4
- PHARMGKB ID:41372-20-7#314-19-2#58-00-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Apo-go; Czech Republic: Apo-go; Denmark: Apo-go; France: Apokinon; Germany: Apo-go, Apomorphin; Greece: Apo-go; Ireland: Apo-go; Italy: Apofin; Netherlands: Apo-go; Portugal: Apo-go; Spain: Apo-go; Sweden: Apo-go; UK: Apo-go, Apomorphine.
North America
USA: Apokyn.
Latin America
Argentina: Apokinon.
Drug combinations
Chemistry
Apomorphine Hydrochloride: C~17~H~17~NO~2~ HCl ½H~2~O. Mw: 312.79 (1) 4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, hemihydrate, (R)-; (2) 6aβ-Aporphine-10,11-diol hydrochloride hemihydrate. CAS-41372-20-7; CAS-314-19-2 (anhydrous); CAS-58-00-4 (apomorphine).
Pharmacologic Category
Antiparkinsonian Agents; Nonergot-derivative Dopamine Receptor Agonists. (ATC-Code: G04BE07; N04BC07).
Mechanism of action
Stimulates postsynaptic D~2~-type receptors within the caudate putamen in the brain.
Therapeutic use
Treatment of hypomobility, «off» episodes in Parkinson’s disease.
Pregnancy and lactiation implications
Use during pregnancy only if clearly needed. Contraindicated during lactation.
Unlabeled use
Treatment of erectile dysfunction.
Contraindications
Hypersensitivity to apomorphine or any component of the formulation. Concomitant use with 5-HT~3~ antagonists. Intravenous administration.
Warnings and precautions
May cause hallucinations, orthostatic hypotension, fibrosis, somnolence. Use with caution in cardiovascular disease (hypotension may cause coronary ischemia), in cerebrovascular disease (hypotension may cause cerebral ischemia), in pre-existing dyskinesias (may be exacerbated), in hepatic impairment, in risk factors for torsade de pointes (hypokalemia, hypomagnesemia, bradycardia, concurrent use of drugs that prolong QTc, or genetic predisposition), or in renal impairment. Pre-treatment with antiemetic is necessary (avoid pre-treatment with antidopaminergic and antiserotonin antiemetic agents). Contains metabisulfite (may cause allergic reactions). Dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome on abrupt withdrawal or significant dosage reduction after long-term use.